FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192908897> ?p ?o ?g. }

• W3192908897 abstract "Objective: To analyze changes in healthcare resource utilization (HCRU) and acute medication use in patients with chronic migraine following treatment with galcanezumab for 1 year. Background: Migraine is a neurologic disease that results in greater HCRU and increased acute medication use. Migraine is associated with disability when inadequately treated. Galcanezumab, a humanized monoclonal antibody, binds calcitonin gene-related peptide and is approved for migraine prevention. Design/Methods: REGAIN (NCT02614261) was a Phase 3, multicenter, randomized, double-blind (DB), placebo (PB)-controlled study of 2 doses of galcanezumab (120 or 240 mg/month given subcutaneously) for prevention of migraine in patients with chronic migraine. The study consisted of a 3-month DB treatment and an 9-month open-label extension (OLE) phase with flexible dosing. At baseline (BL), patients reported migraine-specific HCRU for the previous 6 months and monthly during the treatment period. Acute medication use for headache was captured daily and estimated on an overall monthly basis. Results: Results are presented by groups, per dose assignment during the DB period: PB, 120-mg galcanezumab (120-mg), and 240-mg galcanezumab (240-mg); 533 patients, 269 patients, and 271 patients were analyzed, respectively. Changes in mean migraine-specific HCRU across BL»DB»OLE phases (per 100 patient-years) included: healthcare professional visits: (PB) 110.7»44.5»29.3, (120-mg) 102.6»29.0»34.0, (240-mg) 143.2»36.0»66.1; emergency room visits: (PB) 21.0»13.9»4.5, (120-mg) 19.3»15.3»4.9, (240-mg) 25.1»15.0»10.6; admissions to hospital: (PB) 1.5»0»1.2, (120-mg) 1.5»0»0, (240-mg) 0.7»0»0; and overnight hospital stays: (PB) 4.9»0»3.0, (120-mg) 3.0»0»0, (240-mg) 3.0»0»0. Mean reductions across time in number of migraine headache days (MHDs)/month with acute medication use for BL»DB, BL»Month 6 OLE, BL»Month 12 OLE included: (PB) [15.5at BL], −2.59, −6.34, −7.04, (120-mg) [15.1 at BL], −4.88, −6.38, −7.62, (240-mg) [14.5 at BL], −4.21, −5.63, −6.77; within-group comparisons were significantly larger for each (p Conclusions: Treatment with galcanezumab resulted in significant reductions in MHDs requiring acute medication use, and migraine-specific HCRU. Disclosure: Dr. Joshi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Lilly, Teva, Supernus, Depomed, Promeus. Dr. Tobin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Ford has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Ford holds stock and/or stock options in Eli Lilly and Company. Dr. Nichols has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Nichols holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Nichols was involved as an investigator. Dr. Nichols holds stock and/or stock options in Eli Lilly and Company. Dr. Foster has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Foster holds stock and/or stock options in Eli Lilly and company. Dr. Ruff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Ruff holds stock and/or stock options in Eli Lilly and Company. Dr. Detke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Detke holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Detke was involved as an investigator. Dr. Aurora has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company." @default.
• W3192908897 created "2021-08-16" @default.
• W3192908897 creator A5000001703 @default.
• W3192908897 creator A5004780619 @default.
• W3192908897 creator A5014291037 @default.
• W3192908897 creator A5046253395 @default.
• W3192908897 creator A5059017023 @default.
• W3192908897 creator A5068884979 @default.
• W3192908897 creator A5083368175 @default.
• W3192908897 creator A5090496829 @default.
• W3192908897 date "2019-04-09" @default.
• W3192908897 modified "2023-09-24" @default.
• W3192908897 title "Galcanezumab Significantly Reduced Health Care Resource Utilization and Acute Medication Use in Patients with Chronic Migraine: Findings from a Phase 3, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension (P1.10-001)" @default.
• W3192908897 hasPublicationYear "2019" @default.
• W3192908897 type Work @default.
• W3192908897 sameAs 3192908897 @default.
• W3192908897 citedByCount "0" @default.
• W3192908897 crossrefType "journal-article" @default.
• W3192908897 hasAuthorship W3192908897A5000001703 @default.
• W3192908897 hasAuthorship W3192908897A5004780619 @default.
• W3192908897 hasAuthorship W3192908897A5014291037 @default.
• W3192908897 hasAuthorship W3192908897A5046253395 @default.
• W3192908897 hasAuthorship W3192908897A5059017023 @default.
• W3192908897 hasAuthorship W3192908897A5068884979 @default.
• W3192908897 hasAuthorship W3192908897A5083368175 @default.
• W3192908897 hasAuthorship W3192908897A5090496829 @default.
• W3192908897 hasConcept C118303440 @default.
• W3192908897 hasConcept C126322002 @default.
• W3192908897 hasConcept C142724271 @default.
• W3192908897 hasConcept C163170386 @default.
• W3192908897 hasConcept C168563851 @default.
• W3192908897 hasConcept C170493617 @default.
• W3192908897 hasConcept C204787440 @default.
• W3192908897 hasConcept C27081682 @default.
• W3192908897 hasConcept C2777288759 @default.
• W3192908897 hasConcept C2778541695 @default.
• W3192908897 hasConcept C2910587157 @default.
• W3192908897 hasConcept C42219234 @default.
• W3192908897 hasConcept C71924100 @default.
• W3192908897 hasConceptScore W3192908897C118303440 @default.
• W3192908897 hasConceptScore W3192908897C126322002 @default.
• W3192908897 hasConceptScore W3192908897C142724271 @default.
• W3192908897 hasConceptScore W3192908897C163170386 @default.
• W3192908897 hasConceptScore W3192908897C168563851 @default.
• W3192908897 hasConceptScore W3192908897C170493617 @default.
• W3192908897 hasConceptScore W3192908897C204787440 @default.
• W3192908897 hasConceptScore W3192908897C27081682 @default.
• W3192908897 hasConceptScore W3192908897C2777288759 @default.
• W3192908897 hasConceptScore W3192908897C2778541695 @default.
• W3192908897 hasConceptScore W3192908897C2910587157 @default.
• W3192908897 hasConceptScore W3192908897C42219234 @default.
• W3192908897 hasConceptScore W3192908897C71924100 @default.
• W3192908897 hasLocation W31929088971 @default.
• W3192908897 hasOpenAccess W3192908897 @default.
• W3192908897 hasPrimaryLocation W31929088971 @default.
• W3192908897 hasRelatedWork W2805739889 @default.
• W3192908897 hasRelatedWork W2808748844 @default.
• W3192908897 hasRelatedWork W2897284151 @default.
• W3192908897 hasRelatedWork W2900030708 @default.
• W3192908897 hasRelatedWork W2912353690 @default.
• W3192908897 hasRelatedWork W2916037536 @default.
• W3192908897 hasRelatedWork W2950025797 @default.
• W3192908897 hasRelatedWork W2953644271 @default.
• W3192908897 hasRelatedWork W2961642254 @default.
• W3192908897 hasRelatedWork W2982561889 @default.
• W3192908897 hasRelatedWork W3000418578 @default.
• W3192908897 hasRelatedWork W3006211681 @default.
• W3192908897 hasRelatedWork W3047736609 @default.
• W3192908897 hasRelatedWork W3093820723 @default.
• W3192908897 hasRelatedWork W3111726044 @default.
• W3192908897 hasRelatedWork W3172467076 @default.
• W3192908897 hasRelatedWork W3191369108 @default.
• W3192908897 hasRelatedWork W3193538914 @default.
• W3192908897 hasRelatedWork W3196376434 @default.
• W3192908897 hasRelatedWork W3210087989 @default.
• W3192908897 hasVolume "92" @default.
• W3192908897 isParatext "false" @default.
• W3192908897 isRetracted "false" @default.
• W3192908897 magId "3192908897" @default.
• W3192908897 workType "article" @default.